donzakimig
Unconfirmed
What stands out
New approach in eczema
- Acts on IL-22, which no approved eczema treatment currently does; also targets IL-13 (like Adbry and Ebglyss)
- Binds to IL-22 (a signal that helps barrier cells repair and respond to inflammation) and IL-13 (a signal molecule that plays a role in allergic inflammation)
Derived from FDA substance registry · UniProt Q9GZX6 · UniProt P35225 · · This is a summary of public records for informational purposes only. It is not medical advice.
History
Earliest recorded event: Mar 7, 2022. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.
- Sep 19, 2025Phase 1/2 trial completed · Basic-science trialA Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) ClinicalTrials.gov NCT05277571
- Jul 17, 2025Phase 1/2 main data collected · Basic-science trialA Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) ClinicalTrials.gov NCT05277571
- Mar 7, 2022Phase 1/2 trial started · Basic-science trialA Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B) ClinicalTrials.gov NCT05277571
Sources
- Trials